This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsInsider TradesNews and TrendsOwnershipShort Interest About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX) Get CPRX alerts:Sign Up Key Stats Today's Range$31.49▼$31.4950-Day Range$31.34▼$31.5152-Week Range$19.05▼$32.56VolumeN/AAverage Volume2.62 million shsMarket Capitalization$3.86 billionP/E Ratio18.10Dividend YieldN/APrice Target$32.00Consensus RatingModerate Buy Company Overview Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations. The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). In addition, Catalyst markets Ruzurgi® (amifampridine) tablets for pediatric LEMS patients. Beyond these approved therapies, Catalyst is advancing its pipeline programs that aim to extend its expertise in ion channel modulators to other rare and difficult-to-treat conditions. Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals went public on the Nasdaq Stock Market. The company focuses its operations on clinical development, regulatory strategy and commercialization activities within the United States. Catalyst continues to explore opportunities for international collaborations and licensing arrangements to broaden patient access to its rare disease portfolio. Catalyst is led by President and Chief Executive Officer Patrick J. McEnany, who brings extensive experience in pharmaceutical product development and commercialization. Under his leadership, the company has strengthened its regulatory and commercial capabilities while advancing its pipeline toward future regulatory filings and potential approvals.AI Generated. May Contain Errors. Read More Catalyst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreCPRX MarketRank™: Catalyst Pharmaceuticals scored higher than 34% of companies evaluated by MarketBeat, and ranked 765th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 2 strong buy ratings, 1 buy rating, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Catalyst Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageCatalyst Pharmaceuticals has received no research coverage in the past 90 days.Read more about Catalyst Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth16.67% Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 16.67% in the coming year, from $2.64 to $3.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 18.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 18.10, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.84.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 0.96. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CPRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Catalyst Pharmaceuticals' insider trading history. Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPRX Stock News HeadlinesItaly's Angelini Pharma completes $4.1 billion state-backed takeover of CatalystJuly 16, 2026 | reuters.comAngelini Pharma Completes Acquisition of Catalyst PharmaceuticalsJuly 16, 2026 | globenewswire.comHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.September 14 at 1:00 AM | Base Camp Trading (Ad)Solaris Energy Infrastructure to join S&P SmallCap 600, replacing Catalyst PharmaJuly 10, 2026 | msn.comSanthera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®July 1, 2026 | finance.yahoo.comVamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical DosesJune 30, 2026 | globenewswire.comCatalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRXJune 24, 2026 | businesswire.comAngelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals StoryMay 20, 2026 | finance.yahoo.comSee More Headlines CPRX Stock Analysis - Frequently Asked Questions How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its earnings results on Thursday, November, 6th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.18. The biopharmaceutical company had revenue of $148.39 million for the quarter, compared to analyst estimates of $136.79 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 35.76% and a net margin of 37.08%. Read the conference call transcript. Is Catalyst Pharmaceuticals doing a stock buyback? Catalyst Pharmaceuticals' board initiated a stock buyback plan on Wednesday, October 1st 2025, which permits the company to buy back $200,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 8.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company's management believes its shares are undervalued. Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' top institutional investors include BlackRock Inc. (15.65%), California State Teachers Retirement System (3.18%), Glazer Capital LLC (2.94%) and Jupiter Topco LLC (1.86%). Insiders that own company stock include Steve Miller, David S Tierney, Brian Elsbernd, Richard J Daly, Gary Ingenito, Alicia Grande, Preethi Sundaram, Carmen Jeffrey Del and Molly Harper. View institutional ownership trends. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings11/06/2025Today9/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CPRX's financial health is in the Green zone, according to TradeSmith. CPRX has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CPRX CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees80Year Founded2002Price Target and Rating Average Price Target for Catalyst Pharmaceuticals$32.00 High Price Target$33.00 Low Price Target$31.50 Potential Upside/Downside+1.6%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$1.74 Trailing P/E Ratio18.10 Forward P/E Ratio11.93 P/E Growth0.96Net Income$214.33 million Net Margins37.08% Pretax Margin49.66% Return on Equity35.76% Return on Assets31.31% Debt Debt-to-Equity RatioN/A Current Ratio7.10 Quick Ratio6.84 Sales & Book Value Annual Sales$596.96 million Price / Sales6.46 Cash Flow$2.92 per share Price / Cash Flow10.77 Book Value$7.76 per share Price / Book4.06Miscellaneous Outstanding Shares122,420,000Free Float109,688,000Market Cap$3.86 billion OptionableOptionable Beta0.74 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CPRX) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredNew Form of AI Could Ignite the ‘Great Wealth Rotation’Marc Chaikin, a 60-year Wall Street veteran who worked alongside Paul Tudor Jones and Steve Cohen, says a new ...Chaikin Analytics | SponsoredElon Musk Predicts This Will be the Next Wave of AINvidia CEO Jensen Huang says the Accelerated AI inflection has arrived. Elon Musk has predicted that 99 percen...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
